Flumazenil in cirrhotic patients in hepatic coma: A randomized double-blind placebo-controlled crossover trial

Authors

  • Dr. Gilles Pomier-Layrargues,

    Corresponding author
    1. Liver Unit, Centre de recherche clinique André-Viallet and Hôpital Saint-Luc, Université de Montréal, Québec H2X 1P1
    • Liver Unit, André-Viallet Clinical Research Center, Hôpital Saint-Luc, 264, René-Lévesque east, Montréal, Québec, Canada H2X 1P1
    Search for more papers by this author
  • J. F. Giguère,

    1. Neuroscience Research Unit, Centre de recherche clinique André-Viallet and Hôpital Saint-Luc, Université de Montréal, Québec H2X 1P1
    Search for more papers by this author
  • J. Lavoie,

    1. Neuroscience Research Unit, Centre de recherche clinique André-Viallet and Hôpital Saint-Luc, Université de Montréal, Québec H2X 1P1
    Search for more papers by this author
  • P. Perney,

    1. Liver Unit, Centre de recherche clinique André-Viallet and Hôpital Saint-Luc, Université de Montréal, Québec H2X 1P1
    Search for more papers by this author
  • S. Gagnon,

    1. Neuroscience Research Unit, Centre de recherche clinique André-Viallet and Hôpital Saint-Luc, Université de Montréal, Québec H2X 1P1
    Search for more papers by this author
  • M. D'Amour,

    1. Neuroscience Research Unit, Centre de recherche clinique André-Viallet and Hôpital Saint-Luc, Université de Montréal, Québec H2X 1P1
    Search for more papers by this author
  • J. Wells,

    1. Northern Regional Forensic Laboratory, Sault Ste-Marie, Ontario, P6A 6V3 Canada
    Search for more papers by this author
  • Roger F. Butterworth

    1. Neuroscience Research Unit, Centre de recherche clinique André-Viallet and Hôpital Saint-Luc, Université de Montréal, Québec H2X 1P1
    Search for more papers by this author

  • This work was presented in part at the Annual Meeting of the American Association for the Study of Liver Diseases, Chicago, November 3, 1992.

Abstract

Previous reports have suggested that “endogenous” benzodiazepines could contribute to neural inhibition in hepatic encephalopathy. RO 15-1788 (flumazenil), a specific antagonist of brain benzodiazepine receptors, could thus reverse the neurological symptoms of hepatic encephalopathy. To test this possibility, we conducted a double-blind, placebo-controlled crossover trial of the efficacy of flumazenil in cirrhotic patients in hepatic coma. Seventy-seven cirrhotic patients in hepatic coma were evaluated. Fifty-six were excluded from the trial because of multiorgan failure or because coma was precipitated by prior use of benzodiazepines, and 21 patients were randomly assigned to the flumazenil group (11 patients) or the placebo group (10 patients). Treatment was administered intravenously as a 20-ml solution (placebo or 2 mg flumazenil); seven patients were crossed over. Clinical status was assessed blindly by two observers, using a modified Glasgow scale, every 15 min for 6 hr. Electroencephalogram tracings obtained before and after drug administration were evaluated blindly by two independent observers. Serum concentrations of benzodiazepines before treatment were measured by means of a fluorescence polarization immunoassay. Improvement in neurological symptoms was observed in six patients treated with flumazenil, whereas none in the placebo group showed improvement (p < 0.05; Fisher's exact test). Improvements in electroencephalogram tracings were demonstrated in four patients treated with flumazenil, compared with two patients in the placebo group (p = NS). Benzodiazepines were found in the serum of four patients treated with flumazenil (two responders and two nonresponders); all of these patients had received pharmaceutical benzodiazepines 4 to 6 days before the trial. We conclude that flumazenil is effective in a subset of highly selected cirrhotic patients with severe hepatic encephalopathy and that this beneficial effect is not related to the presence of benzodiazepines in the blood. (Hepatology 1994;19:32–37).

Ancillary